Skip to main content
. 2009 May 18;27(21):3503–3509. doi: 10.1200/JCO.2008.19.3789

Fig 1.

Fig 1.

Progression-free survival (yellow line; median, 1.8 years; 95% CI, 1.3 to 2.8 years) from date of first intra-arterial/blood-brain barrier disruption treatment (149 patients, 93 have experienced disease progression) with 95% CI (blue lines). Symbols on lines indicate censored observations.